Observational studyJACC. Cardiovascular imaging2018
Visceral Adiposity in Psoriasis is Associated With Vascular Inflammation by
Observational study in JACC. Cardiovascular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Atherogenic Lipoprotein Burden, Metabolic Stress and Immune Activation Associated with Coronary Atherosclerosis in Patients with Psoriasis.International journal of molecular sciences · 2026Article
- From skin to heart: a state-of-the-art perspective on psoriasis-driven cardiovascular comorbidities.Frontiers in immunology · 2026Review
- Cardiovascular disease risk in psoriatic disease: mechanisms and implications for clinical practice.Current opinion in rheumatology · 2025Review
- Cardiodermatology: the heart of the connection between the skin and cardiovascular disease.Nature reviews. Cardiology · 2025Review
- Effects on Lipid Profile after One Year of Apremilast Therapy in Patients with Psoriasis: A Monocentric Experience.Life (Basel, Switzerland) · 2024Article
- Impact of GLP-1 Receptor Agonists on Psoriasis and Cardiovascular Comorbidities: A Narrative Review.Psoriasis (Auckland, N.Z.) · 2024Review
- Visceral adipose tissue phenotype and hypoadiponectinemia are associated with aortic Fluorine-18 fluorodeoxyglucose uptake in patients with familial dyslipidemias.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Prevalence of Atherosclerosis in Psoriatic Patients Detected with Epiaortic Color Doppler Ultrasound and Computed Tomography Angiography.Dermatology practical & conceptual · 2022Article
- Study of the Visceral Adipose Tissue in a Cohort of Patients with Moderate-Severe Psoriasis Treated with Biological Therapy.Dermatology practical & conceptual · 2022Article
- New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies.The Journal of investigative dermatology · 2021Review
- Psoriasis and Cardiovascular Disease: Novel Mechanisms and Evolving Therapeutics.Current atherosclerosis reports · 2021Review
- The relation between visceral fat markers and cardiometabolic disease risks in psoriasis patients.Northern clinics of Istanbul · 2021Article
- Chronic inflammation in psoriasis promotes visceral adiposity associated with noncalcified coronary burden over time.JCI insight · 2020Observational
- Chronic inflammation, cardiometabolic diseases and effects of treatment: Psoriasis as a human model.Trends in cardiovascular medicine · 2020Review
- Oxidized Lipids and Lipoprotein Dysfunction in Psoriasis.Journal of psoriasis and psoriatic arthritis · 2020Article
- Novel Positron Emission Tomography Tracers for Imaging Vascular Inflammation.Current cardiology reports · 2020Review
- Serum active 1,25(OH)Atherosclerosis · 2019Observational
- Psoriasis-Related Visceral Adiposity and Arterial Inflammation: A New Adiposity Disease Entity?JACC. Cardiovascular imaging · 2018Article
- Potential Immunological Links Between Psoriasis and Cardiovascular Disease.Frontiers in immunology · 2018Review
Corrections and comments
- Commented on by
Authors and funding
18 authors at 4 institutions in 1 country.
Funding
Abstract
objectivesThe authors sought to examine the relationship between visceral adipose tissue (VAT) and vascular inflammation (VI) by
backgroundPSO, a chronic inflammatory skin disease, is associated with VI by
methodsConsecutive PSO patients (N = 77) underwent
resultsThe cohort was middle aged (51.8 ± 12.6 years), predominantly male (n = 44, 57%), had low cardiovascular risk by Framingham 10-year risk (median 4 years [interquartile range (IQR): 2 to 7 years]), and mild-to-moderate skin disease (5.2 [IQR: 3.0 to 8.5]). PSO disease severity associated with VAT (β = 0.33; p = 0.004) beyond SAT (β = 0.30; p = 0.005). VAT (β = 0.55; p < 0.001), but not SAT (β = 0.15; p = 0.11), associated with VI beyond cardiovascular risk factors. We followed a subset of severe PSO patients treated aggressively for PSO and observed improvement in PSO severity and VAT, which was associated with an improvement in VI at 1 year beyond cardiovascular risk factors (β = 0.53; p = 0.049).
conclusionsVolume-based CT measurement of VAT may capture metabolic risk associated with VI compared to subcutaneous adipose tissue in PSO. PSO treatment associated with a decrease in VAT as well as decrease in VI suggesting VAT as a relevant biomarker related to VI in PSO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.